SUBSCRIBE
SUBSCRIBE
News   Business

Roche, reMYND Sign $637M Early-Stage Parkinson, Alzheimer Deal

September 7, 2010 | 
1 min read
LONDON, Sept 7 (Reuters) - Roche (ROG.VX) boosted its early-stage central nervous system (CNS) drug pipeline on Tuesday by signing a drug development deal for new Parkinson's and Alzheimer's disease medicines with Belgium's reMYND.
Alliances
Roche
MORE ON THIS TOPIC
Contemporary art collage of woman sitting in the lotus position, cloud, pillows against the background of the night sky. Concept of healthy lifestyle and sport. Good and relaxing sleep. Copy space.
Mergers & acquisitions
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
November 14, 2025
 · 
1 min read
 · 
Annalee Armstrong
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Mergers & acquisitions
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Different business strategies. Various solutions. Splitting opinions. Choosing way. Movement options. Separation of directions. Dilemma concept. Two diverging paths of arrows. 3d render
Vaccines
Pfizer Reportedly Planning To Divest BioNTech Stake
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Shanghai.China-Feb.25th 2022: Pfizer company sign on office building. Pharmaceutical and biotechnology corporation
Mergers & acquisitions
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
November 13, 2025
 · 
1 min read
 · 
Annalee Armstrong